Nanobiotix
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esop… Read more
Market Cap & Net Worth: Nanobiotix (NBTX)
Nanobiotix (NASDAQ:NBTX) has a market capitalization of $1.55 Billion ($1.55 Billion) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7358 globally and #3933 in its home market, demonstrating a -20.06% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nanobiotix's stock price $32.08 by its total outstanding shares 48387950 (48.39 Million).
Nanobiotix Market Cap History: 2020 to 2026
Nanobiotix's market capitalization history from 2020 to 2026. Data shows growth from $798.40 Million to $1.55 Billion (12.84% CAGR).
Index Memberships
Nanobiotix is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.04% | #203 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #828 of 3165 |
Weight: Nanobiotix's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Nanobiotix Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nanobiotix's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
-11.96x
Nanobiotix's market cap is -11.96 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $798.40 Million | $50.00K | -$33.62 Million | 15968.02x | N/A |
| 2021 | $391.94 Million | $2.65 Million | -$47.00 Million | 148.07x | N/A |
| 2022 | $177.58 Million | $4.78 Million | -$57.04 Million | 37.18x | N/A |
| 2023 | $352.26 Million | $36.21 Million | -$39.70 Million | 9.73x | N/A |
| 2024 | $138.87 Million | $-11.61 Million | -$68.13 Million | -11.96x | N/A |
Competitor Companies of NBTX by Market Capitalization
Companies near Nanobiotix in the global market cap rankings as of March 18, 2026.
Key companies related to Nanobiotix by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Nanobiotix Historical Marketcap From 2020 to 2026
Between 2020 and today, Nanobiotix's market cap moved from $798.40 Million to $ 1.55 Billion, with a yearly change of 12.84%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.55 Billion | +38.75% |
| 2025 | $1.12 Billion | +705.57% |
| 2024 | $138.87 Million | -60.58% |
| 2023 | $352.26 Million | +98.37% |
| 2022 | $177.58 Million | -54.69% |
| 2021 | $391.94 Million | -50.91% |
| 2020 | $798.40 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Nanobiotix was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.55 Billion USD |
| MoneyControl | $1.55 Billion USD |
| MarketWatch | $1.55 Billion USD |
| marketcap.company | $1.55 Billion USD |
| Reuters | $1.55 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.